Loading viewer...
investor_presentation
Format: PDF investor_presentation
Arcellx is a cell therapy company developing novel synthetic binding domain platforms including ddCAR and ARC-SparX for treating solid tumors and hematologic malignancies. The company reported a 100% overall response rate in a Phase 1 multiple myeloma study and has partnered with Kite to leverage commercial and manufacturing expertise.
presentation
AXA
investor_presentation
Ashok Leyland